Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC
Shots:
- The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in patients with LA or mNSCLC after prior TKI therapy
- NKMax will sponsor the study while Merck KGaA will supply cetuximab (250 mg/m2- wq- IV) for P- I/IIa trial in NSCLC patients. The 1EPs of the study is to assess the safety and drug tolerance of SNK01 while 2EPs is to get efficacy assessments on the combination treatments
- Both the companies will have access to the data of the clinical study
Ref: GlobeNewswire | Image: Merck KGaA
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com